Phase 2 N=66 Refractory Chronic Cough Improvement Via NAL ER (RIVER)
Refractory Chronic Cough
Primary: Relative Change From Baseline in 24-hour Cough Frequency at Day 21 — -64.92; -9.36 coughs per hour — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 pAF for the Treatment of Osteoarthritis
Osteo Arthritis Knee
Primary: Repeat Allogeneic Intra-articular Injection Within 6 Months. — 6; 7 Participants
Phase 2 N=526 A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox
Monkeypox
Primary: Vaccinia Virus Specific Plaque Reduction Neutralization Test (PRNT) Geometric Mean Titer (GMT) — 470.3; 295.7; 293.2 titer — p=<0.001
Phase 2 N=111 Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Brenner Tumor · Malignant Ascites · Malignant Pleural Effusion
Primary: Progression Free Survival (PFS) — 15.4; 14.3 Months — p=0.31
Phase 2 N=71 Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections
Drug Use · Opioid-use Disorder
Primary: Illicit Opioid Use — 0.434; 0.360 Proportion of UDS samples
Phase 2 N=963 RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms
Long COVID-19 · Long COVID
Primary: Percentage of Participants Who Improved in Cognitive Dysfunction Symptom Cluster, as Measured by Patient-Reported Outcomes Measurement Information System (PROMIS)…
Phase 2 N=15 Sublingual Cannabidiol for Anxiety
Anxiety
Primary: Change From Baseline in Self-Reported Anxiety as Assessed by the Beck Anxiety Inventory (BAI) — 20.97; 22.50; 21.00; 6.88 Score — p=<0.001
Phase 2 N=243 A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
Depressive Disorder, Major
Primary: Change From Baseline in MADRS Total Score at Week 6 — -12.0; -7.8; -11.9; -12.3 units on a scale — p=0.2645
Phase 2 N=530 Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction
ST Elevation Myocardial Infarction · Inflammatory Response · Myocardial Reperfusion Injury
Primary: Final Infarct Size — 5; 6 % of LV
Phase 2 N=190 A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Primary: Overall Survival (OS) — 8.08; 4.76; 6.67 months — p=0.7689
Phase 2 N=176 Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis
Plantar Fibromatosis
Primary: Change From Baseline to Day 57 in the Foot Function Index (FFI) Pain Subscale Score — -9.844; -8.417 score on a scale — p=0.274
Phase 2 N=24 A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP
Coronary Heart Disease
Primary: Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax Model — 0.7191; 0.5478; 0.4512; 0.3901 ratio serum levels of IL-6 — p=0.0011
Phase 2 N=44 Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis
Non Alcoholic Steatohepatitis · Fibrosis
Primary: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 — 9; 4 Participants
Phase 2 N=30 Rosacea and Ivermectin
Rosacea
Primary: Adherence - MEMs Cap — 21; 6; 15; 12 Participants
Phase 2 N=31 A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Coronary Heart Disease · Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Primary: Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax Model — 0.8602; 0.7558; 0.7002; 0.6657 ratio serum levels of IL-6 — p=0.0817